Univ. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR9017 - CIIL - Center for Infection and Immunity of Lille, F-59000 Lille, France.
Microbes Infect. 2022 Nov-Dec;24(8):105043. doi: 10.1016/j.micinf.2022.105043. Epub 2022 Sep 6.
2021 was the year of the 100th anniversary of the first administration of the Bacillus Calmette-Guérin (BCG) to a human being. It was the start of a long journey of the world's most widely used vaccine and the oldest vaccine still in use. More than 4 billion children have been vaccinated with BCG for protection against tuberculosis. However, over the years it became apparent that BCG also has beneficial non-specific effects. As such, it provides protection against various heterologous infectious and non-infectious diseases and is used to treat non-muscle-invasive bladder cancer. As BCG was developed at the Institut Pasteur de Lille by Albert Calmette and Camille Guérin, the Institute has celebrated this important anniversary with an international scientific symposium on all aspects of BCG, held from November 17 to 19, 2021 at the Institut Pasteur de Lille. It covered BCG against tuberculosis and described novel vaccine approaches, the effect of BCG against heterologous infections, including BCG and COVID-19, the effect of BCG against cancer, and BCG against auto-immune and inflammatory diseases. To discuss these areas, the symposium gathered close to 200 participants from all five continents, 2/3 on-line. This article presents the highlights of this 3rd International Symposium on BCG.
2021 年是人类首次接种卡介苗（BCG）一百周年。这标志着世界上使用最广泛、历史最悠久的疫苗的漫长旅程的开始。已有超过 40 亿儿童接种 BCG 以预防结核病。然而，多年来，人们逐渐认识到 BCG 还具有有益的非特异性作用。因此，它为预防各种异源感染性和非感染性疾病提供了保护，并被用于治疗非肌肉浸润性膀胱癌。由于卡介苗是由阿尔贝·卡尔梅特（Albert Calmette）和卡米尔·介林（Camille Guérin）在里尔巴斯德研究所开发的，该研究所于 2021 年 11 月 17 日至 19 日在里尔巴斯德研究所举行了一次国际科学研讨会，庆祝这一重要周年，会议涵盖了卡介苗对结核病的作用以及新型疫苗方法、卡介苗对异源感染的作用，包括卡介苗和 COVID-19、卡介苗对癌症的作用以及卡介苗对自身免疫性和炎症性疾病的作用。为了讨论这些领域，研讨会聚集了来自五大洲的近 200 名参与者，其中 2/3 是在线参加的。本文介绍了第三届卡介苗国际研讨会的重点内容。
